Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.

Petrikova, L; Slezakova, K; Sninska, Z; Harvanova, L; Martisova, M; Hatalova, A; Mistrik, M; Batorova, A; Mladosievicova, B

Petrikova, L; Slezakova, K; Sninska, Z; Harvanova, L; Martisova, M; Hatalova, A; Mistrik, M; Batorova, A; Mladosievicova, B.

Bratisl Lek Listy ; 122(8): 531-537, 2021.

Article in En | MEDLINE | ID: mdl-34282617

Subject(s)

Antineoplastic Agents; Cardiovascular Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Adult; Aged; Antineoplastic Agents/adverse effects; Cardiovascular Diseases/chemically induced; Cardiovascular Diseases/epidemiology; Humans; Imatinib Mesylate/adverse effects; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Lipids; Middle Aged; Protein Kinase Inhibitors/adverse effects; Pyrimidines; Retrospective Studies; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Antineoplastic Agents Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Humans / Middle aged Language: En Journal: Bratisl Lek Listy Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google